Arcapta Neohaler, Hirobriz Breezhaler, Onbrez Breezhaler, Oslif Breezhaler (indacaterol) is a small molecule pharmaceutical. Indacaterol was first approved as Arcapta Neohaler on 2009-11-29. It is used to treat chronic bronchitis and pulmonary emphysema in the USA. It has been approved in Europe to treat chronic obstructive pulmonary disease. The pharmaceutical is active against beta-2 adrenergic receptor. In addition, it is known to target beta-1 adrenergic receptor. Hirobriz breezhaler, onbrez breezhaler, oslif breezhaler's patents are valid until 2028-10-11 (FDA).
|Trade Name||Hirobriz Breezhaler, Onbrez Breezhaler, Oslif Breezhaler|
|Indication||chronic bronchitis, chronic obstructive pulmonary disease, pulmonary emphysema|
|Drug Class||Bronchodilators (phenethylamine derivatives)|